Kornimate/medical-research-clean huggingface dataset:
study in covid-19 patients with ivermectin (corvette-01)

Conditions: Covid19

Summary: treatment of mild covid-19 is basically performed at an outpatient clinic, then when the symptom and clinical findings exacerbate to a moderate level, patients are admitted. there is no standard treatment for mild cases. this study will investigate whether ivermectin administration suppresses the replication of sars-cov-2 in mild to moderate covid-19 by investigating the negative rate of sars-cov-2 pcr by a randomized controlled trial. subjects are assigned to two groups, the placebo group, and the ivermectin group. the target number of each treatment arm is 120, a total of 240 cases. a single oral administration of 200 ㎍/kg of ivermectin or an ivermectin-free placebo will be administered on an empty stomach. time to negativization of sars-cov-2 pcr as the primary endpoint with additional efficacy and safety of the process will be investigated.


Eligibility criteria:
inclusion criteria: 1. a person who has been diagnosed with covid-19 (including asymptomatic) by the covid-19 pcr test (sars-cov-2 nucleic acid detection) within 3 days before the qualification test. 2. a person with oxygen saturation (spo2) in the room air of 95% or more. 3. a person who are 20 years or older at the time of obtaining consent. 4. a person who weigh 40 kg or more at the time of qualification test. 5. a person who understands the content of this clinical trial and can obtain written consent to participate in the clinical trial. exclusion criteria: 1. a woman who is in lactation period or who may be pregnant, or those who do not agree to prevent pregnancy by medically appropriate means for up to 7 days after study drug administration. medically appropriate contraception means that using a combination of two or more of the following: not having sexual intercourse, taking surgical sterilization such as vasectomy or intrauterine device, taking oral contraceptive, using condom. 2. a person who has severe liver damage (ast or alt at the time of qualification test is more than 3 times the upper limit of institutional standard and total bilirubin is more than twice the upper limit of institutional standard value), renal disorder (egfr of eligibility test value 30 ml/min/1.73m2 or less). 3. a person with hypersensitivity to ivermectin. 4. a person with a history of severe drug allergies such as stevens-johnson syndrome, toxic epidermal necrolysis. 5. a person who has received the prohibited medication within the past month (within the past 6 months for biologics), or those who need to use the prohibited medication during the clinical trial period. 6. those who are scheduled to receive sars-cov-2 vaccination from the date of consent to the end of the follow-up period. 7. a person who are currently participating in other clinical trials or who have participated in other clinical trials within 30 days before obtaining consent. 8. in addition, a person who is determined to be unsuitable as a subject of this clinical trial by the principal investigator."
goal achievement after utilizing an anti-pcsk9 antibody in statin intolerant subjects -2

Conditions: Hyperlipidemia

Summary: the primary objective was to evaluate the effect of 12 weeks of subcutaneous (sc) evolocumab every 2 weeks (q2w) and monthly (qm), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (ldl-c) in hypercholesterolemic adults unable to tolerate an effective dose of a statin (hmg-coa (5-hydroxy-3-methylglutaryl-coenzyme a) reductase inhibitors).


Eligibility criteria:
inclusion criteria: * male or female ≥ 18 to ≤ 80 years of age * not on a statin or on a low dose statin with stable dose for at least 4 weeks * history of intolerance to at least 2 statins * subject not at ldl-c goal * lipid lowering therapy has been stable prior to enrolment for at least 4 weeks. * fasting triglycerides ≤ 400 mg/dl exclusion criteria: * new york heart association (nyha) iii or iv heart failure * uncontrolled cardiac arrhythmia * uncontrolled hypertension * type 1 diabetes, poorly controlled type 2 diabetes * uncontrolled hypothyroidism or hyperthyroidism

Keywords: high cholesterol, treatment for high cholesterol, lowering cholesterol, lowering high cholesterol, hypercholesterolemia
optimization of insomnia treatment in primary care

Conditions: Insomnia Disorder

Summary: the primary objective of this pragmatic clinical trial is to evaluate the efficacy, feasibility, and adaptability of pharmacological and non-pharmacological treatments for insomnia disorder, delivered in primary care clinics. the second objective is to evaluate the efficacy of a sequential (stepped care) approach for persistent insomnia.


Eligibility criteria:
inclusion criteria: * aged 18 years or over * meeting criteria for insomnia disorder * registered patient at one of the primary care clinics participating in the study * fluent in french * computer and internet access exclusion criteria: * unstable or untreated psychiatric disorder * lifetime psychotic or bipolar disorder * current suicide risk * progressive or unstable medical disorder * untreated sleep disorder other than insomnia * use of medication altering sleep * irregular or atypical sleep-wake schedule * current or planned pregnancy

Keywords: insomnia pragmatic clinical trial drug therapy cognitive behavior therapy primary care
the c-mac video laryngoscope helps presbyopic anesthetists

Conditions: Presbyopia

Summary: endotracheal intubation is the de facto gold standard for airway management especially in neonatal and pediatric anesthesia . an efficient neonatal airway management is challenging even in the most experienced hands and the prevalence of difficult intubation in pediatric anesthesia varied greatly on a wide range.

neonatal intubation is a life-saving procedure, which requires skilled operator but still may cause direct tissue trauma and precipitate adverse reactions. however, intubation with videolaryngoscope (vl) requires less force than with a direct laryngoscope to minimize the possibility of these adverse events. the recent brazilian recommendations for management of pediatrics difficult airways included proper assessment, preparation, positioning, pre-oxygenation, minimizing trauma, maintenance of arterial oxygenation and the implementation of the advanced tools as vl, flexible intubating bronchoscopy, and supraglottic devices. the recent british recommendations also advised for the use vl with an age-adapted standard blade as first choice for tracheal intubation and the use of a stylet to reinforce and preshape tracheal tubes in case of the use of hyperangulated vl blades . considering the recent interest in assessing the performance of various vls in pediatric anesthesia, the c-mac® (karl storz, germany) vl with standard miller blade sizes #0 and #1, is a widely used in neonates and infants for its provision of superior-quality glottis view in comparison to the mcgrathtm mac size #1 blade and direct laryngoscopy. presbyopia is defined as disordered eye adjustment function and affects middle aged people leading to difficult viewing close objects and is corrected with magnifying lens. earlier studies documented that presbyopic aged anesthetists find difficulty when trying to view a patient's larynx at a close distance and this difficulty is surely magnified on dealing with intubation of neonates and children

Eligibility criteria:
inclusion criteria: * pediatric patients whom scheduled for surgical procedures under general inhalation anesthesia exclusion criteria: * patients older than 12 months * patients with mallampati score of 3 or 4, * patients had abnormal airway and obstructive sleep apnea, * manifestations of upper respiratory tract infection or uncompensated cardiopulmonary diseases * patients with asa grade \>iii were excluded from this study.
study to demonstrate equivalent efficacy and to compare safety of biosimilar adalimumab (gp2017) and humira

Conditions: Plaque Type Psoriasis

Summary: the aim of the study is to demonstrate equivalent efficacy and similarity in the safety profile of gp2017 and humira® in patients with moderate to severe chronic plaque-type psoriasis.

the aim of this study (treatment period 1) was to demonstrate equivalent efficacy, primarily based on the pasi75 response rate at week 16, and similar safety of the proposed biosimilar gp2017 and humira in patients with moderate to severe chronic plaque-type psoriasis at the end of treatment period 1, after 17 weeks of study treatment. the subsequent treatment period 2 (week 17 to week 35) and the extension period (week 35 to week 51) were performed to evaluate long-term effects, including immunogenicity (i.e. adas), and the effects of repeated switching between gp2017 and humira.

Eligibility criteria:
inclusion criteria: * men or women at least 18 years of age at time of screening * chronic plaque-type psoriasis diagnosed for at least 6 months before randomization * moderate to severe psoriasis as defined at baseline by: * pasi score of 12 or greater * investigator´s global assessment score of 3 or greater (based on a scale of 0 - 4) and, * body surface area affected by plaque-type psoriasis of 10% or greater * chronic plaque-type psoriasis patients who have previously received phototherapy or systemic psoriasis therapy at least once or who are candidates for such therapies in the opinion of the investigator. exclusion criteria: * forms of psoriasis other than chronic plaque-type * drug-induced psoriasis * ongoing use of prohibited psoriasis treatments * previous exposure to adalimumab * active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of treatment with adalimumab other in-/exclusion criteria may apply

Keywords: plaque type psoriasis equivalent efficacy safety and immunogenicity gp2017 humira®
does potassium iodide (sski) reduce vascularity in graves' thyroidectomy?

Conditions: Graves Disease

Summary: the purpose of this research is to find out if sski (potassium iodide) reduces vascularity (the number and concentration of blood vessels) and improves how well patients do after surgery for removal of their whole thyroid gland in graves' disease (an autoimmune disease that is a common cause of hyperthyroidism).

patients with graves' disease and goiters tend to have very vascular thyroid glands, which increases operative bleeding risks/rates. many surgeons treat these patients with preoperative sski which is believed to decrease the vascularity, which in turn may decrease bleeding risks. however, there has been no quantitative data published on whether this is a real effect with true clinical benefit, in either animal or human models with sski. there have been some studies in europe studying lugol's solution, a different formulation of iodine, which show some decreased vascularity using color doppler or measurements of cd34 cells.

Eligibility criteria:
inclusion criteria: * individuals diagnosed with graves' disease undergoing total thyroidectomy for cure of disease. exclusion criteria: * no graves' disease * \< 18 years old
use of thalidomide in patients with arachnoiditis

Conditions: Arachnoiditis

Summary: this pilot study will evaluate whether thalidomide decreases pain in patients with arachnoiditis.

arachnoiditis, a neuropathic disease caused by inflamation of the arachnoid membrane that surrounds and protects the spinal nerves,can result in a debilitating state that is characterized by numbing and tingling, stinging and burning in the lower back or legs, and possible muscle cramps, twitching and spasms. current treatments are not always effective in treating the pain associated with arachnoiditis. recent research has indicated that a group of chemicals called cytokines that are produced by various cells in the body may be responsible for generating the pain response. medications that effect the release of cytokines or block the action of cytokines may reduce the pain response. various anti-cytokine medications are now being used to treat painful disease states such as rheumotoid arthritis and crohn's disease. in this study the anti-cytokine medication, thalidomide, is being evaluated for it's effect in treating pain associated with arachnoiditis.

Eligibility criteria:
inclusion criteria: * radiographically confirmed arachnoiditis * involvement of the lower limb(s) exclusion criteria: * subjects with baseline peripheral neuropathy to include diabetic neuropathy and other metabolic or toxic neuropathies.

Keywords: cytokine arachnoiditis neuropathic pain tumor necrosis factor
the effect of nlp on pain before uterine curettage due to the fetal demise

Conditions: Nursing Caries; Pain, Acute; Pregnancy Loss

Summary: pregnancy termination is a difficult and painful procedure can be done by medically or uterine curettage. studies have been conducted to reduce the anxiety of women undergoing pregnancy termination, but there are no publications on topics such as anxiety, pain perception, and pain catastrophizing. neuro linguistic programming (nlp) has been called "the art and science of personal excellence", "the study of subjective experience". nlp helps us understand the difference between our actions that produce mediocre results or failure and those that require success or excellence. nlp: "how do i do something i do well?", "how can i do it better?", "how can i gain skills that i admire in others? it addresses questions like ". it is important to note that nlp is not limited to observable behavior. our way of thinking, that is, all experience and it also includes the mental processes that control our actions. by dealing with the entire structure of a person's experience (in fact, their motivation), it tries to shape the thought processes, emotions and beliefs that result in a behavior. it is especially about our communication with ourselves as well as with others. no study was planned on pain and pain perception during pregnancy termination by uterine curettage by teaching the nlp technique to the patients.

in this randomized controlled study, the group of patients who underwent uterine curettage with the indication of pregnancy termination in the septic service of the department of gynecology and obstetrics of şanlıurfa training and research hospital will be divided into two groups and nlp training will be given before uterine curettage in a double-blind manner and vas (visual pain scale) after uterine curettage. evaluation will be made using the fear of pain scale-3 and the pain catastrophizing scale. nlp training will be given for approximately 20 minutes, and the group that will not receive nlp training will remain silent for 20 minutes. the results will be compared.

Eligibility criteria:
inclusion criteria: * over 18 years of age, non-pregnant, with an indication for pregnancy termination; those who agreed to participate in the study, patients who understand and can speak turkish exclusion criteria: * patients who do not meet the inclusion criteria or who have had a previous pregnancy termination

Keywords: nlp uterin curettage pain
effect of montelukast on the expression and variation of tgf-β for children with mild persistent asthma

Conditions: Asthma

Summary: the objective of our research is to observe the effect of cysteinyl leukotriene receptor antagonist on the expression and variation of tgf-β1 levels and mrna expression in children with mild persistent asthma in their plasma and t lymphocyte, to discuss the role of tgf-β1 in the pathogenesis of bronchial asthma in children and to evaluate the function of regulation of leukotriene receptor antagonist on asthma in children.

the majority pediatric asthma patients in shanghai are mild persistent asthma. these patients require controller medications every day to achieve and maintain control. leukotriene receptor antagonist is one of the options which have been recommended to use as a mono controller therapy. patient satisfaction and compliance was better with montelukast, attributed to oral intake and convenience. owing to its easy and simple oral once a day administration montelukast was found to be advantageous over ics. on the other hand, recent studies have shown that there is a considerable degree of airway remodeling in peripheral airways in patients with mild asthma.the new information points out the need for large, long term studies on the treatment of mild persistent asthma, with an emphasis on exacerbations, remodeling, and the relationship between these outcomes and markers of asthma control. tgf-β participates in the initiation and propagation of inflammatory and immune responses in the airways. the leukotrienes exert their biologic actions by binding to and activating specific receptors. montelukast, a cysteinyl leukotriene 1(cyslt1) receptor antagonist, acts on ltc4, ltd4 and lte4, and, therefore, on airway inflammation and bronchoconstriction. some results suggest that low dose of montelukast may modulate the parameters of inflammation and fibrosis.in this study we try to determine the effects of lower dose montelukast on the expression and variation of tgf-β in induced sputum and t lymphocyte for children with mild persistent asthma. drug in the study provide by msd. we have done induced sputum procedure in our past study. reagent can be bought from company.

Eligibility criteria:
inclusion criteria: * patients aged 6 to 14 years with a history of physician-diagnosed asthma (at least 3 episodes of asthma symptoms during the previous year, including, but not limited to cough, wheezing, and shortness of breath) exclusion criteria: * patients were not in good health, other than asthma, on the basis of results of medical history, physical examination, and routine laboratory tests.

Keywords: asthma child transforming growth factor beta(tgf-β) leukotriene antagonists(montelukast)
the effects of dexmedetomidine on inflammatory mediators after one lung ventilation during video-assisted thoracoscopic surgery

Conditions: One Lung Ventilation in Thoracic Surgery

Summary: during lung surgery, mechanical one-lung ventilation is usually mandatory to provide appropriate surgical condition. however, not only mechanical ventilation is associated with inflammatory response, but also one lung ventilation will result in detrimental effects such as ischemia and reperfusion injury, and systemic inflammatory responses. dexmedetomidine is an alpha-2 selective agonist. it was reported that dexmedetomidine decreased reperfusion injury, reduce the release of proinflammatory mediator and protected lungs from reperfusion injury in esophageal cancer patients who undergoing one lung ventilation from reducing oxidative stress metabolites. however, other details of protective effects is still unknown. high mobility group box 1 (hmgb1) is an important proinflammatory factor. it was found to be related to ventilator induced lung injury in several condition. animal studies also showed that dexmedetomidine reduces the expression of messenger ribonucleic acid in lipopolysaccharide-activated macrophage so that decrease the amount of hmgb1 release. however, clinical trials about these are still lacking. in this study, we will investigate the protective effects of dexmedetomidine to patients undergoing video-assisted thoracoscopic surgery, especially on the specific inflammatory markers- plasma hmgb1 and other inflammatory cytokines (eg. interleukin-1. interleukin-6). this will let us to know the role of hmgb1 during one-lung ventilation injury and the effect of dexmedetomidine in regulating the release of hmgb1. this study will become a basis of further medical therapy in treating inflammation.


Eligibility criteria:
inclusion criteria: 1. american society of anesthesiologists physical classification i-ii patients who receive vats lobectomy 2. patients with the following will be excluded: * suspect of infection, eg. white blood cell count\> 10000 ; fever\> 38.3℃ * preoperative cardiac or renal dysfunction, eg. new york heart association \>= ii, estimated glomerular filtration rate\< 60 * predisposing liver dysfunction, eg. aspartate aminotransferase or alanine aminotransferase \>100; total bilirubin\> 2mg/dl; \>= child b liver cirrhosis

Keywords: inflammatory cytokine protective effect dexmedetomidine precedex one lung ventilation ischemia-reperfusion
integrative yoga therapy for patients with chronic pain and psychological distress

Conditions: Chronic Pain; Psychological Distress

Summary: this study will be a randomized wait list controlled trial studying the efficacy of an integrative yoga therapy for patients with chronic pain and psychological distress. individualised yoga program will consist of a 8-week guided self-help program. this study will primarily investigate whether an individually tailored yoga can be beneficial for patients suffering from chronic pain reducing pain, anxiety depression, while improving overall quality of life.


Eligibility criteria:
inclusion criteria: * experienced pain for \> 3 months * experiences at least one type of psychological distress such as: depression, anxiety, insomnia or stress * willing to provide informed consent exclusion criteria: * severe medical or psychiatric conditions * alcohol or substance abuse * active suicidality * terminal illness
a comparison of fluconazole and amphotericin b in the treatment of cryptococcal meningitis

Conditions: Meningitis, Cryptococcal; HIV Infections

Summary: to compare the safety and effectiveness of fluconazole and amphotericin b, alone or in combination with flucytosine, as treatment for acute cryptococcal meningitis.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * immunosuppressant therapy. * antiviral therapy such as zidovudine. * prophylaxis for pneumocystis carinii pneumonia. concurrent treatment: allowed: * radiation therapy for mucocutaneous kaposi's sarcoma. written informed consent must be obtained for each patient, either from the patient himself or from the patient's legal guardian. * no prior systemic antifungal therapy for cryptococcosis. * relapse after prior therapy. * success of prior therapy must have been documented by negative cerebrospinal fluid (csf) culture at the end of therapy. following prior therapy, such patients may not have received more than 1 mg/kg/wk amphotericin b in the 4 weeks before entry into study. prior medication: allowed: * immunosuppressant therapy. * antiviral therapy (such as zidovudine). * prophylaxis for pneumocystis carinii pneumonia. exclusion criteria co-existing condition: patients with the following are excluded: * evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis. * history of allergy to or intolerance of imidazoles, azoles, or amphotericin b. * moderate or severe liver disease. * comatose. * unlikely to survive more than 2 weeks. * any exceptions to these prohibitions of concomitant medications must be approved by pfizer central research. concurrent medication: excluded: * coumadin-type anticoagulants. * oral hypoglycemics. * barbiturates. * phenytoin. * immunostimulants. * investigational drugs or approved (licensed) drugs for investigational indications. * any exceptions to these prohibitions of concomitant medications must be approved by pfizer central research. * excluded within 4 weeks of study entry: * greater than 1 mg/kg/wk amphotericin b. concurrent treatment: excluded: * lymphocyte replacement. patients with the following are excluded: * evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis. * history of allergy to or intolerance of imidazoles, azoles, or amphotericin b. * moderate or severe liver disease. * comatose. * unlikely to survive more than 2 weeks. prior medication: excluded: * coumadin-type anticoagulants. * oral hypoglycemics. * barbiturates. * phenytoin. * immunostimulants. * investigational drugs or approved (licensed) drugs for investigational indications. * excluded within 4 weeks of study entry: * greater than 1 mg/kg/wk amphotericin b. prior treatment: excluded: * lymphocyte replacement.

Keywords: aids-related opportunistic infections meningitis cryptococcosis drug therapy, combination fluconazole flucytosine acquired immunodeficiency syndrome amphotericin b